Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development

11/02/2021 | 06:30am EST

- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development -

- Pathway Development Consortium is building a collaboration of patients, industry, regulators, academia, payers and other stakeholders -

WASHINGTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- The Pathway Development Consortium (PDC), a new public-private collaboration founded by REGENXBIO Inc. (Nasdaq: RGNX) and Solid Biosciences Inc. (Nasdaq: SLDB), today announced the publication of a draft white paper, Draft Framework for AAV Gene Therapy Development, which proposes a framework that can be applied to AAV gene therapies to facilitate the use of the accelerated approval pathway at the US Food and Drug Administration (FDA). The white paper identifies different categories of AAV gene therapies that target the underlying monogenetic changes that cause disease and proposes generalized approaches that would clarify the evidence needed to support FDA approval. The PDC is actively seeking feedback from key stakeholders on this framework at info@pathwaydevelopmentconsortium.org.

The publication of the white paper coincides with the formal launch of the PDC, a multistakeholder initiative which aims to identify, develop, expand and maintain pathways to effective therapies for patients diagnosed early in life with rare diseases. The PDC seeks to achieve these goals by bringing together a broad and diverse group of stakeholders from the rare disease and AAV gene therapy communities, including patients, industry, regulators, academia and payers, among others, for meaningful scientific and policy discussions.

“The Agency recognizes the importance of broad stakeholder engagement to facilitate and expedite the development of AAV gene therapies for rare diseases,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research (CBER). “FDA looks forward to hearing more about this consortium’s efforts to help bring promising gene therapies to patients in need.”

“The Pathway Development Consortium is embarking on critical work aiming to expeditiously advance AAV gene therapies for patients living with rare diseases,” said Rachel Sherman, MD, MPH, President at Rachel Sherman Partners and former Principal Deputy Commissioner at the FDA. “After a long history of building public-private collaborations throughout my career at FDA, I have seen firsthand the impact that can be made when all stakeholders come together to create groundbreaking solutions. This draft framework proposed by the PDC is an innovative approach to facilitate the development and regulatory approval of important AAV gene therapies.”

“The Pathway Development Consortium has the unique potential to bring together the diverse perspectives in the rare disease community with the interest of the patient at the forefront,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO and co-founder of the PDC, in partnership with Ilan Ganot, Co-Founder, President and Chief Executive Officer of Solid Biosciences. “We founded the PDC together because we share the vision that this collaboration can meaningfully guide how AAV-based gene therapy treatments can be more rapidly made available to patients. The ability to regularly dialogue with the FDA is critical and we are grateful for their support of this endeavor,” said Ganot.

The PDC’s activities kicked off with a roundtable discussion held in April 2021 to focus on Duchenne muscular dystrophy (Duchenne), a progressive muscle-wasting genetic disease that primarily affects boys. Children with Duchenne are typically diagnosed between the ages of 3 and 5 years old, lose the ability to walk by their early-teens and have a life expectancy of approximately 25 years. The roundtable focused on finding a path forward for meaningful clinical endpoints in clinical trials and brought together more than 120 attendees from the Duchenne patient community, industry, academia and the FDA. In September 2021, the PDC’s first white paper was published, identifying areas where attention is needed to facilitate development of AAV gene therapies for Duchenne.

About Pathway Development Consortium
The Pathway Development Consortium (PDC) aims to guide the recent decades of AAV gene therapy research into a future of innovative, potentially life-saving therapies. The PDC’s goal is to foster collaboration and partnership among patients, industry, regulators, academia, payers and other stakeholders. For this reason, REGENXBIO and Solid Biosciences joined together to launch the PDC with the vision to construct an ideal pathway to ensure that all born with serious genetic conditions can find their way to effective AAV gene therapies. To learn more, visit https://www.pathwaydevelopmentconsortium.org/.

Pathway Development Consortium Contact:
Annie Ganot, VP, Patient Advocacy, Solid Biosciences Inc.
Nina Hunter, PhD, VP, Regulatory Affairs & Science Policy, REGENXBIO Inc.
(202) 503-9060

Media Contact:
Caitlin Lowie, VP, Communications and IR, Solid Biosciences Inc.
Tricia Truehart, VP, Investor Relations and Corporate Communications, REGENXBIO Inc.

Source: Solid Biosciences Inc.; The Pathway Development Consortium; REGENXBIO Inc.

2021 GlobeNewswire, Inc., source Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
REGENXBIO INC. 2.69% 27.06 Delayed Quote.-19.42%
SOLID BIOSCIENCES INC. -6.08% 1.385 Delayed Quote.-15.43%
01/13LETTER TO THE DUCHENNE COMMUNITY : IGNITE DMD Phase I/II Clinical Trial and 2022 Prioritie..
01/10SOLID BIOSCIENCES : Outlines its Strategic Priorities for 2022 and Announces Corporate Upd..
01/10SOLID BIOSCIENCES INC. : Results of Operations and Financial Condition, Other Events, Fina..
01/10Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Up..
01/10Solid Biosciences Inc. Names Ian F. Smith as Executive Chair
01/06Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
01/04Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resource..
01/04Solid Biosciences Inc. Appoints Allison Bogosian as Senior Vice President, Human Resour..
2021SOLID BIOSCIENCES INC.(NASDAQGS : SLDB) added to NASDAQ Biotechnology Index
2021LETTER TO THE DUCHENNE COMMUNITY : IGNITE DMD Phase I/II Clinical Trial and Pipeline Updat..
More news
Analyst Recommendations on SOLID BIOSCIENCES INC.
More recommendations
Financials (USD)
Sales 2021 12,6 M - -
Net income 2021 -76,1 M - -
Net cash 2021 83,7 M - -
P/E ratio 2021 -2,07x
Yield 2021 -
Capitalization 163 M 163 M -
EV / Sales 2021 6,29x
EV / Sales 2022 -6,48x
Nbr of Employees 70
Free-Float -
Duration : Period :
Solid Biosciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOLID BIOSCIENCES INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 1,48 $
Average target price 8,50 $
Spread / Average Target 474%
EPS Revisions
Managers and Directors
Ilan Ganot President, Chief Executive Officer & Director
Stephen J. DiPalma Chief Financial Officer & Treasurer
Ian Frederick Smith Executive Chairman
Carl Morris Senior Vice President-Research & Development
Cathryn M. Clary Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.-0.66%54 178
BIONTECH SE-34.36%40 873